Ligand validation:4ANQ

VGH: 3-[(1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-(1-piperidin-4-yl-1H-pyrazol-4-yl)pyridin-2-amine

VGH is a Ligand Of Interest in 4ANQ designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
4ANQ_VGH_A_9000	45%	10%	0.145	0.877	2.48	1.84	10	7	2	0	100%	1
4ANS_VGH_A_9000	42%	17%	0.156	0.875	2.25	1.38	13	5	2	0	100%	1
2XP2_VGH_A_9000	37%	11%	0.168	0.867	2.47	1.76	11	6	2	0	100%	1
5AAB_VGH_A_9000	32%	11%	0.179	0.854	2.43	1.81	12	6	2	0	100%	1
2YFX_VGH_A_9000	31%	12%	0.152	0.819	2.33	1.81	10	7	2	0	100%	1
3ZBF_VGH_A_3000	44%	11%	0.159	0.884	2.26	1.91	12	9	1	0	100%	1
6IMZ_VGH_A_205	32%	15%	0.156	0.828	1.9	1.87	4	8	1	0	100%	0.85

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.